For thousands of women affected by blood clots after taking Yaz, Yasmin, Ocella or Gianvi, the past few years have been a waiting game to recover much-needed compensation from Bayer.
DrugRisk has learned the world’s largest endocrinology organization has called for new testing of popular testosterone replacement therapy drugs after studies show they may have serious health risks.
German drug maker Boehringer Ingelheim issued a press release this week boasting that its popular blood thinning drug Pradaxa has been approved in the 100th country for stroke prevention in atrial fibrillation patients.
On Friday, pharmaceutical giant Bayer released its 2013 annual report. Hidden deep within the boasts of profits and drugs currently under development, was a section that admitted how the company’s birth control pills Yaz and Yasmin have hurt thousands of women.
DrugRisk continues to track news about the popular atrial fibrillation blood thinner drug Pradaxa. And lately, that news isn’t positive.
With health experts around the world warning about the dangers of blood clots from Yaz and Yasmin birth control in recent years, many thought the message was clearly out.
Within a month of multiple reports questioning the safety of popular low-T drugs like AndroGel, Axiron and AndroDerm, several lawsuits have already been filed against the manufacturers by those injured.
Last month, DrugRisk reported that the popular atrial fibrillation blood thinner Pradaxa was facing tough times: a new study announced by the FDA, a growing number of lawsuits alleging the drug caused internal bleeding injury or death, and trials scheduled to start later this year.
For the past several years, drug maker Bayer has been hit with thousands of lawsuits from women who suffered blood clots or gallbladder disease while taking the birth control drugs Yaz and Yasmin.
Following several recent studies questioning the safety of popular testosterone replacement therapy (TRT) drugs, The FDA last month announced it will open a new investigation into heart attack, stroke and death risks.